Like other members of the TZDs family, ROSI’s anti-cancer effect is yielded via both PPAR-γ-dependent and PPAR-γ-independent pathways, as well as both in monotherapy and in combined treatment with chemotherapeutics. Here, PPARG is linked to cancer.